Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
- PMID: 28715827
- DOI: 10.7326/ACPJC-2017-167-2-005
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
Comment on
-
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Diabetes Obes Metab. 2017 Aug;19(8):1106-1115. doi: 10.1111/dom.12917. Epub 2017 Mar 31. Diabetes Obes Metab. 2017. PMID: 28240446
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical